PANEL DISCUSSION: How Prepared is the Industry for More Gene Therapy Approvals on the Horizon?

Time: 5:45 pm
day: Day Two


As more gene therapy companies are entering or are in late-stage phase III trials, the industry need to prepare to navigate the challenges this will bring, including demands on manufacturing capacity, coming to agreements with payers, and ensuring patients are able to access these therapies. This panel will discuss:

  • Current payer perspectives into gene therapy pricing and reimbursement
  • Building out internal manufacturing capacity for commercial products
  • Exploring the concept of centres of excellence versus multi-centre gene therapy